🚀 VC round data is live in beta, check it out!
Alkaloid Valuation Multiples
Discover revenue and EBITDA valuation multiples for Alkaloid and similar public comparables like Aarti Pharmalabs, Eton Pharmaceuticals, Sunmax Biotechnology, Zentiva and more.
Alkaloid Overview
About Alkaloid
Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals. It derives maximum revenue from Pharmaceuticals products segment.
Founded
1936
HQ
Employees
3.0K
Website
Financials (FY)
EV
$728M
Alkaloid Financials
Alkaloid reported last fiscal year revenue of $366M and EBITDA of $38M.
In the same fiscal year, Alkaloid generated $166M in gross profit, $38M in EBITDA, and $32M in net income.
Alkaloid P&L
In the most recent fiscal year, Alkaloid reported revenue of $366M and EBITDA of $38M.
Alkaloid expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $366M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $166M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 45% | XXX | XXX | XXX |
| EBITDA | — | XXX | $38M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 10% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 12% | XXX | XXX | XXX |
| Net Profit | — | XXX | $32M | XXX | XXX | XXX |
| Net Margin | — | XXX | 9% | XXX | XXX | XXX |
| Net Debt | — | — | $34M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Alkaloid Stock Performance
Alkaloid has current market cap of $678M, and enterprise value of $728M.
Market Cap Evolution
Alkaloid's stock price is $481.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $728M | $678M | -1.3% | XXX | XXX | XXX | $23.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlkaloid Valuation Multiples
Alkaloid trades at 2.0x EV/Revenue multiple, and 19.0x EV/EBITDA.
Alkaloid Financial Valuation Multiples
As of April 18, 2026, Alkaloid has market cap of $678M and EV of $728M.
Equity research analysts estimate Alkaloid's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alkaloid has a P/E ratio of 20.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $678M | XXX | $678M | XXX | XXX | XXX |
| EV (current) | $728M | XXX | $728M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 19.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 16.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.4x | XXX | XXX | XXX |
| P/E | — | XXX | 20.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 80.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alkaloid Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Alkaloid Margins & Growth Rates
Alkaloid's revenue in the last fiscal year grew by 15%.
Alkaloid's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Alkaloid Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 9% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 29% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Alkaloid Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alkaloid | XXX | XXX | XXX | XXX | XXX | XXX |
| Aarti Pharmalabs | XXX | XXX | XXX | XXX | XXX | XXX |
| Eton Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Sunmax Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Zentiva | XXX | XXX | XXX | XXX | XXX | XXX |
| Prime Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alkaloid M&A Activity
Alkaloid acquired XXX companies to date.
Last acquisition by Alkaloid was on XXXXXXXX, XXXXX. Alkaloid acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Alkaloid
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAlkaloid Investment Activity
Alkaloid invested in XXX companies to date.
Alkaloid made its latest investment on XXXXXXXX, XXXXX. Alkaloid invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Alkaloid
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alkaloid
| When was Alkaloid founded? | Alkaloid was founded in 1936. |
| Where is Alkaloid headquartered? | Alkaloid is headquartered in North Macedonia. |
| How many employees does Alkaloid have? | As of today, Alkaloid has over 3K employees. |
| Is Alkaloid publicly listed? | Yes, Alkaloid is a public company listed on Macedonian Stock Exchange. |
| What is the stock symbol of Alkaloid? | Alkaloid trades under ALK ticker. |
| Who are competitors of Alkaloid? | Alkaloid main competitors are Aarti Pharmalabs, Eton Pharmaceuticals, Sunmax Biotechnology, Zentiva. |
| What is the current market cap of Alkaloid? | Alkaloid's current market cap is $678M. |
| What is the current revenue of Alkaloid? | Alkaloid's last fiscal year revenue is $366M. |
| What is the current EV/Revenue multiple of Alkaloid? | Current revenue multiple of Alkaloid is 2.0x. |
| Is Alkaloid profitable? | No, Alkaloid is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.